Showing 4171-4180 of 23240 results for "".
Assessing Sex-Based Treatment Responses to Gepants In Migraine Management
https://reachmd.com/programs/frontlines-migraine/assessing-sex-based-treatment-responses-to-gepants-in-migraine-management/36157/A secondary analysis of eight clinical trials assessed the efficacy of ubrogepant and atogepant in both acute and preventive migraine treatments. Dive into these findings and explore implications for the future of migraine care.Navigating Gastrointestinal Impacts of GLP-1 Receptor Agonists
https://reachmd.com/programs/gi-insights/navigating-gastrointestinal-impacts-of-glp-1-receptor-agonists/35943/GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in RocGEP Testing for Cutaneous Squamous Cell Carcinoma
https://reachmd.com/series/updates-in-skin-cancer/gep-testing-for-cutaneous-squamous-cell-carcinoma/35599/Emily Ruiz, MD, MPH, FAAD, director of the High-Risk Cancer Clinic at Dana-Farber Cancer Institute, discusses utilizing gene expression profiling (GEP) to risk stratify tumors in cutaneous squamous cell carcinoma patients.Tailoring Approaches to Pediatric Rheumatic Disease: Best Practices for Long-Term Management
https://reachmd.com/programs/living-rheum/tailoring-approaches-to-pediatric-rheumatic-disease-best-practices-for-long-term-management/32789/For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink SchoolDupixent Approved for Spontaneous Urticaria
https://reachmd.com/series/dermwire-tv/dupixent-approved-for-spontaneous-urticaria/35635/In this week's DermwireTV, the FDA approves the first new therapy for spontaneous urticaria in more than 10 years; a new study examines investigational oral Icotrokinra in adolescents with plaque psoriasis; and Practical Dermatology launches a new series addressing trends and innovations in the treaDupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://reachmd.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.Acne and Rosacea: Dr. Baldwin
https://reachmd.com/conferences/maui-derm-hawaii-2025/acne-and-rosacea-dr-baldwin/32693/Hilary Baldwin, MD, talks about a topic that she did not have time to cover during "Update 2025: Acne and Rosacea" at Maui Derm 2025—emergency contraception in patients on isotretinoin.American Academy of Dermatology 2024
Meeting Wrap-Uphttps://reachmd.com/cme/dermatology/meeting-coverage-aad-2024/24461/Practical Dermatology® was at the American Academy of Dermatology 2024 Annual Meeting in San Diego (AAD 2024) reporting on the latest research findings on innovative therapies and insights into managing complex dermatological disorders. From pioneering trials showcasing the efficacy of novel topicalKey Therapeutic Insights on Semaglutide in Adolescent Obesity
https://reachmd.com/programs/diabetes-discourse/key-therapeutic-insights-on-semaglutide-in-adolescent-obesity/14621/Find out more about the effectiveness of once-daily semaglutide in adolescents with obesity.New Horizons In ALS: Insights on Emerging Treatment Options
https://reachmd.com/programs/clinicians-roundtable/new-horizons-in-als-insights-on-emerging-treatment-options/14230/What’s on the horizon for new treatment options for patients with ALS? Find out.